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Abstract
Background: Pathological Gambling (PG) is an impulse control disorder often comorbid with
other psychopathology, particularly bipolar spectrum disorders, attention deficit/hyperactivity
disorder, obsessive-compulsive disorder (OCD) and substance abuse. This paper reviews the
published literature on the pharmacological management of PG, highlighting how clinical and
subclinical comorbid psychopathology influences the choice of pharmacological treatment.
Methods: Using Medline, the authors reviewed relevant articles published on this topic from1995
to 2005, focusing on the best-designed studies for inclusion.
Results: Much of the literature on PG-treatment presupposes different theories regarding this
disorder. Data suggest the utility of differentiating the pharmacotherapy of pathological gamblers
in light of their comorbid profile, specifically assessing for comorbid bipolar, ADHD, OCD, and
substance abuse disorders.
Conclusion: Decisions about pharmacological treatment of PG should take into account current
and previous comorbid disorders which influence treatment selection.
Background
Pathological gambling (PG) is an impulse control disor-
der not otherwise specified (ICD-NOS) [1] that is charac-
terized by recurrent and maladaptive patterns of gambling
behavior and significantly disrupts the patient's function-
ing in the personal, familial, or vocational spheres. It is
assumed to be a chronic disorder, with a clinical course
that is continuous, unremitting, or episodic [2]. Its preva-
lence ranges from 1% to 3% of the US adult population
[3,4], and there has been a dramatic increase in PG over
the last decade, due to the legalization and availability of
new forms of gambling in most Western countries.
Despite a prevalence even higher than that of schizophre-
nia or bipolar disorder, little is known regarding effective
treatments, particularly pharmacotherapies, for PG. In
addition, currently, no medications have been approved
by the U.S. Food and Drug Administration for the treat-
ment of this impairing and common disorder.
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sented by the high rates of comorbidity among patholog-
ical gamblers. The majority of these patients, at least those
seeking treatment, have been found to score significantly
higher than control populations on measures of depres-
sion [5], and have shown high incidences of various psy-
chiatric disorders, including bipolar, anxiety and
substance use disorders [6]. This frequent comorbidity is
not surprising if we focus on the psychopathological core
features of PG: impulsivity, compulsive drive to gamble,
addictive features such as withdrawal symptoms during
gambling abstinence, and bipolar features such as urges,
pleasure seeking and decreased judgment due to unrealis-
tic appraisal of the individuals' own abilities. Several
authors have associated some of these core features to
neurobiological data and clinical aspects of treatment-
response, and have conceptualized PG as belonging to dif-
ferent spectrum classification models, in which the main
psychiatric disorders of reference are obsessive-compul-
sive disorder (OCD), addictive disorders, and affective
disorders. These models of categorization provide the
basis and rationale for the use of specific pharmacological
treatments in pathological gamblers. In addition, they
may also suggest, according to consistent findings
reported in some trials, the presence of specific subgroups
of patients with similar core features, comorbid profiles
and treatment-responses within the population of patho-
logical gamblers.
Main classification models for Pathological Gambling
The traditional nosographic model includes PG within
ICDs-NOS; evidence supporting this categorization is the
elevated rates of comorbidity between these disorders,
and the similarity in phenomenology between PG and
other ICDs. These similarities include the temptation to
perform some behavior notwithstanding its detrimental
consequences for the person, a growing emotional ten-
sion before performing the act, a gratifying feeling while
performing the behavior, and sometimes, a feeling of guilt
following the behavior. However, in addition to this clas-
sification model, at least three other conceptualizations
have been historically proposed for the classification of
PG [7].
PG has also been conceptualized as an obsessive-compul-
sive (OC) spectrum disorder, within the impulsive cluster
[8]. Patients with OC spectrum disorders, in fact, experi-
ence unpleasant feelings and physiological activation that
result in an intense desire to perform a specific behavior
in order to relieve the unpleasant feelings [9-11]; this is
the case in PG. In addition, a reduced capacity to resist
gambling thoughts would lead to excessive gambling, in
particular in the advanced phases of the disorder [12].
However, these patients differ from patients with OCD in
important ways. Gambling behavior and thoughts are
often experienced by these patients as ego-syntonic, while
OCD obsessions and compulsions are generally ego-dys-
tonic. In addition, the excessive doubt, frequently experi-
enced by OCD patients [10,13,14] as well as their
compulsions, characterized by harm avoidance, risk aver-
sion and anticipatory anxiety [14], are not characteristic of
pathological gamblers. OC spectrum disorders do differ
along the dimension of risk aversion vs risk taking; the
compulsive disorders are characterized by an overestima-
tion of harm and by risk aversion while the impulsive dis-
orders are characterized by an underestimation of risk and
by risk seeking.
PG has occasionally been characterized as an affective
spectrum disorder. Notwithstanding the high rates of
comorbidity between depression and PG [15-18] and the
frequent presence of suicidality and suicidal ideation
among these patients [19-22], the link between these two
disorders has been questioned by several authors. With
regard to suicidality, for example, is possible to guess that
high levels of impulsivity, often present in pathological
gamblers, may lead to suicidality independently from
depression. On the other hand, data from several studies
suggest that PG is a bipolar spectrum disorder and, con-
sidering that the comorbidity between these two disorders
is estimated to be approximately 24% [23], have led some
authors to the conclusion that impulsivity and bipolarity
are related [24]. Other authors have stressed that certain
PG core features resemble some characteristic aspects of
bipolar spectrum disorders. The experience of the urge in
PG, for example, may represent a potential overlap
between pathological gamblers and patients with bipolar
spectrum disorders. The pleasure seeking and impaired
judgment resulting from an unrealistic evaluation of one's
own abilities that are seen in pathological gamblers
resemble characteristics seen in individuals with bipolar
disorder [25]. Both disorders involve potentially harmful
but pleasurable behavior and acting without forethought.
Finally, these disorders generally have their onset in early
adulthood and have an episodic course.
Another interesting model proposed for PG is as a non-
substance addiction. PG and substance use disorders, in
fact, share several features. Important features common to
these mental disorders include the intense desire to satisfy
a need; the lack of control over the substance use or
behavior; certain aspects of abstinence and tolerance; the
obsessive thoughts about the substance use or the activity;
and the continuous engagement in the behavior despite
experiencing social and occupational consequences [26].
For example, pathological gamblers often increase the fre-
quency of their bets or the amount of money gambled in
order to achieve the desired level of excitement and this
behavior is suggestive of drug tolerance. Finally, high
comorbidity rates between PG and substance use disor-Page 2 of 9
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and dependence, give further support to this model.
Being able to explain PG using different models does not
necessarily imply that these models are incompatible;
rather it may suggest the possible presence of subtypes of
pathological gamblers. Being able to identify different
subtypes that share similar phenomenological and clini-
cal characteristics might not only lead to a better under-
standing of this disorder, but better use of
pharmacological options. In fact, if it is possible to distin-
guish different clinical subtypes, it would seem logical
that pharmacological treatments could be optimized to fit
specific subgroups. Several core symptoms of PG could
conceivably be targeted for treatment: impulsive symp-
toms, compulsive symptoms, bipolar symptoms and
addictive symptoms. A rational pharmacological choice
would take into account which of these symptom
domains seem to dominate, as well as a patient's comor-
bid disorders, because treatment should ultimately target
all clinically significant symptoms in the individual
patient. Actually, the ability of specific pharmacological
treatments to improve gambling behavior in some
patients and the lack of efficacy or, even the worsening, in
some other patients, suggests the presence of specific sub-
types of pathological gamblers and supports the possibil-
ity of targeting pharmacotherapy based on the patient's
unique symptoms and comorbidities.
Methods
In this review we used a Medline search to locate the pub-
lished articles from 1995 to 2005. The most weight was
given to double blind, placebo-controlled studies due to
the high placebo response rates reported in most trials;
open-label studies and case-reports have also been
included. In addition, we focused on studies that were rel-
evant to understanding the connection between the char-
acteristics of the samples, the comorbidity profiles, the
drug administrated and the clinical response achieved.
The variety of drugs employed in the treatment of PG
includes serotonin reuptake inhibitors (SRIs) and other
antidepressants, mood stabilizers, and opioid antago-
nists. We did not include the atypical antipsychotics since
there has been little systematic investigation of them in
PG, and there is little evidence of their effectiveness in this
disorder.
Results
Serotonin Reuptake Inhibitors (see Tables 1, 2  - additional 
file: 1)
Serotonin reuptake inhibitors, considered first-line treat-
ment for OCD [34], have been shown to be effective in
treating impulsivity in other ICDs and OC spectrum dis-
orders [35-39]. Furthermore, neurobiological data indi-
cating serotonergic dysfunction in PG [40-42], a
phenomenological link to compulsivity [8], and a possi-
ble response in PG to the SRI clomipramine [43], have
given further support for the use of the SRIs in this disor-
der. To date, the following SRI compounds have been
tested for the treatment of PG: fluvoxamine, paroxetine,
citalopram and clomipramine.
Fluvoxamine
The possible efficacy of fluvoxamine in the treatment of
PG has been tested by three randomized, placebo-control-
led studies. In an initial pilot study conducted by our
group [44], 16 pathological gamblers were enrolled in a
single-blind, 16-week, crossover study at the end of which
7 of the 10 completers receiving fluvoxamine were found
to be treatment responders with notable improvements
on the main outcome measures: the Pathological Gam-
bling Yale-Brown Obsessive Compulsive Scale (PG-
YBOCS, reduction ≥ 25%)[45] and the Clinical Global
Impressions Scale[46] (CGI score 2, very much improved
or 1, much improved). The mean fluvoxamine dose at the
end of the study was 207 mg/day and the 7 treatment
responders reported a total abstinence from gambling
behavior. It is noteworthy that among the 3 fluvoxamine
non-responders, 2 patients had a history of cyclothymia,
the mildest form of bipolar disorder, which raised the
possibility of a symptomatologic exacerbation with this
SRI as well as a gambling relapse.
In a subsequent double-blind crossover study [47] com-
paring fluvoxamine to placebo, a group of 10 male
patients completed the 16-week trial. The percent
improvement on the CGI-PG was significantly greater for
fluvoxamine (40.6%) than for placebo (16.6%), and the
percent improvement on PG-YBOCS, although not statis-
tically significant, was greater for the group treated with
fluvoxamine (33.4%) than with placebo (28%). The aver-
age fluvoxamine dosage at the end point was 195 mg/day.
In this study, however, the patient group was limited and
relatively homogenous, excluding gamblers with current
comorbid drug or alcohol abuse as well as bipolar I and II
patients.
In another double-blind, parallel, placebo-controlled trial
[48], 13 pathological gamblers of the 32 enrolled com-
pleted a 6 month-study, receiving a mean fluvoxamine
dosage of 200 mg/ day at endpoint. Blanco and col-
leagues, however, reported a statistically significant
improvement with fluvoxamine compared with placebo
only for males and for young pathological gamblers. Fur-
thermore, a high drop-out rate in the fluvoxamine group,
a high rate of placebo response (59%) and the concomi-
tant psychotherapy received by some patients complicate
the interpretation of the results. We cannot rule out that,
notwithstanding the absence of another current Axis I dis-Page 3 of 9
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bid psychopathology might have decreased the
homogeneity of the sample, suggesting different subtypes
of pathological gamblers.
Taken as a whole, fluvoxamine trials support the efficacy
of this compound in PG, although in some cases the effi-
cacy was not statistically significant, as compared with
placebo. Drug dosages ranged between 100 and 250 mg/
day. It's noteworthy that at least in the first study different
patterns of treatment-response were related to different
comorbidity profiles.
Paroxetine
In a study conducted by Kim and colleagues, 45 patients
were randomized to paroxetine up to 60 mg/day or to pla-
cebo in a double-blind, 8-week trial [49]. At endpoint,
there were greater, and statistically significant, improve-
ments (G-SAS [50], p = .042 and CGI, p = .025) in the par-
oxetine group than in the placebo group. As the authors
reported, all subjects had low baseline scores at the Ham-
ilton Depression Rating Scale (HDRS) [51] and Hamilton
Anxiety Rating Scale (HARS) [52] suggesting low comor-
bidity rates in the sample for depression and anxiety. In
addition, patients with other Axis I disorders were
excluded from the study. However, it is possible to assume
that the low presence of comorbidity might in turn be
indicative of a specific subgroup of gamblers particularly
sensitive to the SRI treatment.
In a later multicenter, double-blind, placebo-controlled
trial [53], Grant and co-workers randomly assigned 76
pathological gamblers to paroxetine, up to 60 mg/day, or
to placebo for 16 weeks. A total of 45 patients completed
the study. The paroxetine group showed a greater percent-
age of responders (59%) at each study visit, compared
with placebo (49%), but failed to demonstrate statistical
significance over placebo on the outcome measures (PG-
CGI scores of 1 or 2). Current Axis I disorders as well as a
past history of bipolar, psychotic, alcohol or substance use
disorders were exclusion criteria. The results of this study
did not replicate the previous findings by Kim and col-
leagues, and found a notable placebo response for patho-
logical gamblers without relevant comorbid conditions.
Grant and colleagues suggested that a possible interpreta-
tion of these results might be the tendency to reduce
unwanted behaviors when greater attention is focused on
them, which might also increase motivation. However,
the presence of subthreshold psychopathology was not
investigated and whether or not this lack of response was
related to particular subthreshold comorbid conditions.
Citalopram
In the only open-label study performed with citalopram
[54], Zimmerman and colleagues reported a clinically sig-
nificant improvement (PG-CGI scores of 1 or 2) for 13 of
the 15 patients participating in the trial. The final mean
dosage of citalopram was approximately 35 mg/day.
Given the design of the study, which did not control for
placebo response, it is not possible to calculate the actual
effect of citalopram. However, it is noteworthy that while
psychotic disorders, mania and hypomania, as well as
drug or alcohol dependence were excluded, depression,
anxiety, eating or impulse-control disorders were not. This
difference could be important in the understanding the
impressive clinical response in this study, suggesting that
these particular comorbid disorders might not represent a
specific contraindication to the use of the SSRIs
Other antidepressants (see Table 3 - additional file: 1)
Nefazodone
In 2002, Pallanti and our group enrolled 14 patients with
PG in an 8-week open-label oral nefazodone trial [55].
The sample included other Axis I comorbid disorders such
as bipolar II, cyclothymia, depression, panic disorder and
social phobia. At the endpoint, 9 of the 12 completers
were classified as responders (reduction ≥ 25% PG-Y-
BOCS and score of 1 or 2 on PG-CGI). The mean endpoint
dosage of nefazodone was 350 mg/ day. This phenylpiper-
azine antidepressant with 5HT2 receptor antagonist prop-
erties and mixed noradrenergic/serotonergic reuptake
inhibitor effects showed a good response profile in this
group of pathological gamblers with other comorbid psy-
chopathology. However, the study design as well as the
limited size of the sample does not allow definitive con-
clusions.
Dopamine Reuptake Inhibitors
More recently, Black reported positive findings in an
open-label trial [56] involving 10 pathological gamblers
treated with bupropion up to 300 mg/day for 8 weeks. All
subjects reported improvement (reduction from 20.3 to
8.8 on the PG-Y-BOCS and score of 1 or 2 on PG-CGI).
Given patients' initial mild to moderate levels of ADHD
traits, the author suggested that bupropion might reduce
impulsiveness and improve attention span. In addition,
he hypothesized that pathological gamblers with comor-
bid ADHD might represent a distinct subgroup of patients
requiring a specific treatment.
Opioid Antagonists (see Table 4 - additional file: 1)
Naltrexone, a long-acting opioid antagonist, is the only
compound in this category that has been found to be
effective in the treatment of PG. This compound blocks
the effect of endogenous endorphins on central opiate
receptors and also inhibits dopamine release in the
nucleus accumbens, acting on neuronal pathways
involved in reward, pleasure and urge. The inhibition of
dopamine release in the nucleus accumbens, through the
disinhibition of γ-aminobutyric acid (GABA) input to thePage 4 of 9
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is one of the most consistent reasons given for the use of
naltrexone in ICDs. Another important pharmacological
action of naltrexone in the central nervous system is the
antagonism of the µ-opioid receptor, which is the site of
action of beta-endorphins, morphine and heroin. Shino-
hara and colleagues [67] have suggested a possible role of
this system in the physiological responses to gambling,
given its involvement in the processing of reward, pleas-
ure and pain. In addition, some neurobiological and neu-
roimaging reports [68,69] would confirm the relationship
between some specific brain areas (nucleus accumbens,
orbitofrontal cortex and motor limbic system), in which
naltrexone is supposed to act, and their physiological role
in the processes of reward and urge, typically abnormal in
pathological gamblers.
So far, the clinical use of naltrexone has shown mixed
results in treating urge related disorders such as alcohol
dependence, OCD, bulimia nervosa, kleptomania, and
self-injurious behaviors [70-74]. In a case report [70] of an
open label treatment, Crockford and el-Guebaly reported
that naltrexone at 50 mg/ day was effective in a patient
suffering from both PG and alcohol dependence. In
another case-report [75], a 55-year-old man with PG and
compulsive shopping markedly improved while taking
100 mg/day of naltrexone. In a 6-week open-label study
[76], 17 pathological gamblers without severe psychiatric
comorbidity showed a statistically significant reduction in
both gambling behavior and urges on a mean dosage of
157 mg/ day of naltrexone. In an 11-week double-blind,
placebo-controlled study [50], 83 patients with PG were
randomly assigned to naltrexone (up to 250 mg/day,
mean final dosage of 188 mg/day), or to placebo. Of the
45 completers receiving naltrexone, 75% showed
improvement on the outcome measures (patient- and cli-
nician-rated CGI), compared to 24% of patients receiving
placebo. The authors reported that depressive symptoms
were mild or absent in the completers receiving naltrex-
one. Furthermore, patients with moderate or higher levels
of gambling urges at baseline had a better response to nal-
trexone than other patients. It is possible to argue that
urges, which represent one of the core symptoms of PG,
might also be the main target of naltrexone. As suggested
by Kim's group, baseline urge level might be used as a
stratification variable that could enhance group differ-
ences in outcome and could also be used to predict
response to naltrexone. However, the side-effect profile of
this compound may be problematic. Since higher naltrex-
one doses are needed in PG treatment than are usually
employed for alcohol and drug dependence, the increase
in transaminase levels must be carefully monitored due to
the risk of hepatotoxicity. In addition, other common
side-effects reduce patient compliance. Currently, research
is being conducted on another opioid receptor antagonist,
nalmefene, to assess its efficacy in treating pathological
gambling with preliminary encouraging findings.
Mood Stabilizers (see Table 5 - additional file: 1)
Evidence of the effectiveness of mood stabilizers in ICDs
has been reported [77-85], suggesting these compounds
can modify, and treat successfully, some core features of
these disorders. In 1980, Moskowitz [86] reported the
effectiveness of lithium in treating 3 pathological gam-
blers with bipolar features. In 1994, Haller and Hinterhu-
ber reported, in a placebo controlled studyl [87], a single
case of chronic PG successfully treated with car-
bamazepine at a dosage of 600 mg/day. Subsequently, a
single-blind placebo-controlled study [88] was conducted
by our group in order to evaluate the efficacy and safety of
lithium and valproate in non-bipolar pathological gam-
blers. At the end of the 14th week, 14 of the 23 patients
receiving lithium (mean dose 795 mg/day) and 11 of the
19 taking valproate (mean dose 870 mg/ day) were con-
sidered responders (PG-CGI and PG-YBOCS). Although
patients with bipolar disorder were excluded from thus
study as well as patients with current alcohol/drug addic-
tion or schizophrenic spectrum disorders, the majority of
patients had a past history of other psychiatric conditions,
including depressive episodes (7/45), alcohol or drug
abuse (23/45), panic disorder (15/45), OCD (9/45), anti-
social personality disorder (8/45) and other ICDs (16/
45). Therefore, even if a specific "anti-impulsive" action of
mood stabilizers may be hypothesized, we have to con-
sider the impact of lifetime comorbidities, which may cur-
rently be subthreshold, when considering treatment-
response data. In addition, although the Structured Clini-
cal Interview for DSM-IV (SCID) [89] was used in the
study to exclude the comorbid bipolar disorders, the accu-
racy of this instrument in detecting bipolar disorder, par-
ticularly type II, is still matter of debate. Consequently,
the possible inclusion of bipolar II patients in the study
should be kept in mind.
Recently, our group conducted the first placebo-control-
led treatment study [90] of sustained-release lithium car-
bonate in pathological gamblers with bipolar spectrum
disorders. Patients with bipolar I disorder were excluded
because it was a placebo-controlled trial, but patients with
diagnoses of bipolar II, bipolar disorder NOS and
cyclothymia were included in the trial. Among the 29
completers at the end of the 10th week, 12 patients
received lithium (mean dose 1150 mg/day) and 17
received placebo. At endpoint, 10/12 patients in the lith-
ium group were considered responders (based on CGI of
1 or 2 and a score reduction of 35% on the PG-YBOCS),
and improvement in impulsive gambling significantly
correlated with increases in affective stability. Of note, the
percentage of placebo responders found in this study
(29%) appears to be significantly lower than that reportedPage 5 of 9
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uate the effectiveness of a mood stabilizer in pathological
gamblers with comorbid bipolar spectrum features con-
firms previous reports of the effectiveness of these com-
pounds in PG, and suggests that there may be significant
advantages in subtyping pathological gamblers. The iden-
tification of bipolar spectrum PG patients is relevant to
the choice of pharmacological treatment; in this subtype,
in fact, a mood stabilizer might have a higher probability
of efficacy than other treatments such as SSRIs, which may
exacerbate affective instability and cause a gambling
relapse.
Recently, Dannon and his group randomized 31 male,
pathological gamblers to topiramate or fluvoxamine
(both titrated up to 200 mg/day) in a 12 week blind-rater
comparison trial [91]. At endpoint, both groups reported
improvement on the PG-CGI, although the improvement
for fluvoxamine did not quite reach statistical significance
(p < 0.08 for fluvoxamine; p < 0.01 for topiramate); there
were no statistically significant differences between the 2
groups. In addition, a larger number of drop-outs were
reported in the fluvoxamine group. Notwithstanding the
lack of a placebo-controlled group and the partial blind
design of this trial, it is noteworthy that a mood stabilizer
was at least as effective as an SSRI in a group of patholog-
ical gamblers without comorbid conditions, providing,
therefore, more than one choice for this specific subgroup
of gamblers.
Among the 18 studies reported, 6 were double-blind, pla-
cebo-controlled studies (4 with SRIs, 1 with naltrexone
and 1 with a mood stabilizer), 3 were single-blind (1 with
an SRI and 1 comparing mood stabilizers, and one com-
paring an SRI with a mood stabilizer), 4 were open-label
(1 with an SRI, 1 with nefazadone, 1 with naltrexone, and
one with bupropion) and 4 were case-reports (2 with nal-
trexone and 2 with mood stabilizers, one of which had a
double blind design).
With regard to reported SRI trials, a total of 127/200 com-
pleted single- and double-blind trials (41 with fluvoxam-
ine and 86 with paroxetine), 15 patients completed an
open-label trial with citalopram (see Tables 1 and 2 - addi-
tional file: 1). In addition, 12 patients received open-label
treatment with nefazodone and 10 patients with bupro-
pion (Table 3 - additional file: 1).
Thirty-six out of forty-five patients completed a double-
blind trial with naltrexone, 14/17 patients completed an
open-label trial (table 4 - additional file: 1), and 2 patients
were reported in 2 different case reports to have received
open label treatment.
Seventy-two out of ninty-seven patients completed single-
and double-blind trials with mood stabilizers (27 with
lithium, 16 with valproate, 12 with topiramate and 17
treated with placebo Table 5), and 4 cases of patients
treated with mood stabilizers were reported, one of which
treated in a double-blind design.
The majority of pathological gamblers have been treated
with SRIs, and these drugs seem to be generally well toler-
ated. Effective does in PG resemble those used in the treat-
ment of OCD; approximately 200 mg/day for
fluvoxamine, and up to 60 mg/day for paroxetine were
effective in PG trials. These studies demonstrated a
marked placebo effect, and therefore they need an ade-
quate period of time (between 8 and 12 weeks) in order
to monitor and assess the improvement achieved. Only
one SRI trial [44] looked at the relationship between
worsening PG symptoms in non-responders and comor-
bid cyclothymia. In all the studies, the efficacy of the SRIs,
when statistically significant, was independent of underly-
ing depressive or anxious comorbidity. This supports the
hypothesis that a serotonin sensitive PG subtype exists in
which the marked impulsivity is driven by serotonergic
dysregulation. In this subtype, the use of an SRI might
normalize the 5-HT dysfunction and improve the clinical
condition. An important exception, however, is the sub-
group of pathological gamblers with bipolar features, for
whom treatment with an SRI could precipitate worsening
of the overall clinical picture. Therefore, although SRIs
have been shown to be effective in patients with mild
obsessive-compulsive, depressive and anxious comorbid-
ity, additional research should be conducted on PG cor-
morbid with bipolar spectrum disorders. In this research,
it would be important to consider not only current comor-
bid diagnoses but also the past history of the patient and
careful attention to other current symptoms to assess the
presence of subthreshold bipolar psychopathology [88].
Future double-blind studies are necessary in order to
acquire further and more detailed information about the
efficacy of the SRIs already employed in the treatment of
PG, as well as of those which have never been tested.
Although only 1 double-blind study has been conducted
in PG with naltrexone, its results may have important
implications. The target of this opioid antagonist seems to
be the urge to gamble. Even if this core symptom is also a
feature of bipolar disorder, it is sensitive to the action of
naltrexone, and its predominance in specific cases might
indicate this opioid antagonist should be considered. In
addition, the presence of comorbid substance and alcohol
abuse/dependence might also suggest that naltrexone
should be tried, as shown by the case reports. However,
although naltrexone has demonstrated specific anti-
impulsive properties, it could be difficult to consider this
drug a first-choice treatment for PG, given the high dosagePage 6 of 9
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and the side-effects profile reported. However, pathologi-
cal gamblers with specific comorbid profiles and without
hepatic diseases may be successfully treated with this opi-
oid antagonist. Finally, promising preliminary findings
[92] have been shown with another opioid antagonist,
nalmefene, which may have better tolerability than nal-
trexone.
The studies conducted with mood stabilizers confirm
what has been postulated about the SRIs. A specific anti-
impulsive property of mood stabilizers can be hypothe-
sized. In addition, the impulsivity may be related to affec-
tive instability and, therefore, a decrease in affective
instability with mood stabilizers might reduce impulsiv-
ity, improving the overall clinical condition. The findings
support the hypothesis of a PG subtype in which the
administration of SRIs would be useless or even worsen
the associated bipolar spectrum symptoms. Specific con-
traindications for the use of mood-stabilizers in PG have
not yet been reported. Although additional confirming
research is necessary, the possible efficacy of these com-
pounds in a wide spectrum of pathological gamblers was
recently supported by an open-label study in which flu-
voxamine and topiramate showed similar efficacy in treat-
ing PG.
The most recent double-blind PG study reported by our
group [92] included only PG patients with comorbid
bipolar II, cyclothymia and bipolar NOS diagnoses. The
recognition of this as a possibly important subgroup of
PG led to this study of the efficacy of lithum in gamblers
with PG and bipolar spectrum disorders. These patients
demonstrated statistically significant improvement com-
pared to placebo on all key outcome measures, with 83%
of the patients on lithium considered responders com-
pared to 29% on placebo, a notably smaller placebo effect
than normally reported in SRIs trials. The inclusion of
adequate clinical instruments and interviews in order to
obtain precise comorbid diagnoses may enable complex
findings to be interpreted and lead to more precisely tar-
geted treatments. Only a minority of studies have done
this. Generally authors prefer to select samples of patients
without other current psychopathology, in order to obtain
samples that are as homogeneous as possible and to have
a sample of "pure" PG patients. However, this procedure,
though excluding complicating comorbid pathologies,
does not exclude the possible influence of the subthresh-
old psychopathology, which may influence the treatment-
response. In addition, such a procedure may lead to treat-
ments which are effective for only a small and atypical
group of pathological gamblers.
Future studies are needed in order to confirm the clinical
validity of dividing pathological gamblers into specific
subgroups. For example, neuroimaging studies might
assess if different subgroups of patients show common
patterns of neuronal activation, metabolism and per-
fusion of specific brain areas.
Conclusion
Treatment data supports the hypothesis that there are spe-
cific subgroups of pathological gamblers. These sub-
groups were suggested by the different models of PG that
were discussed. The assessment of clinical and subclinical
comorbid psychopathology seems to represent a rational
and valid approach to selecting pharmacological treat-
ment for the different subgroups. However, few studies
reported to date have specifically explored the comorbid
profile of pathological gamblers. Nevertheless, positive
findings shown in some studies and interesting observa-
tions reported in other studies, suggest this approach sup-
port is promising and might lead to more effective
treatments for specific subgroups of gamblers.
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